Allogeneic iNKT Cell Therapy (agenT-797) After SCT

Part of paid clinical trials in Madison, Wisconsin.

Sponsor
University of Wisconsin, Madison
Study ID
NCT07758218
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • agenT-797 — DRUG
    agenT-797 is an off-the-shelf cell therapy consisting of ≥ 95% allogeneic human unmodified iNKT cells isolated from 1 healthy donor mononuclear cell apheresis unit and expanded ex vivo.

Study Details

The goal of this clinical trial is to learn if agenT-797 is safe to use on people undergoing allogenic hematological stem cell transplantation (SCT). The main questions it aims to answer are: * Is agenT-797 safe to use? * What medical problems do participants have when taking agenT-797? Participants will receive an infusion of agenT-797 about 7 days after their allogenic SCT.

Key Dates

First listed
Aug 11, 2026
Start date
Oct 31, 2026
Status verified
Aug 2026
Primary completion
Oct 31, 2029
Completion
Oct 31, 2029

Study Design

Enrollment
22 participants (estimated)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
SUPPORTIVE_CARE

Arms

  • Experimental: Allogeneic iNKT Cells
    3+3 Dose escalation of agenT-797 will be administered by intravenous infusion every 2 weeks.

Primary Outcome Measure

Number Of Participants With Treatment-related Adverse Events [ Time Frame: Baseline through Day 29 post cell infusion ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Wisconsin - MadisonMadisonWisconsin53792
Cancer Connect
[email protected]
800-622-8922

Find similar trials in Madison, WI

Nationwide
Leukemia (other) trialsOncology trialsBlood cancer trials
By condition
Leukemia (other)
By specialty
OncologyBlood cancer
By research site
University of Wisconsin - Madison· Madison, WI

Related Studies